Lexaria Bioscience CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Lexaria Bioscience Corp. reported a significant increase in net losses for fiscal year 2025, driven by substantial investments in DehydraTECH R&D for diabetes, weight loss, and hypertension treatments, while facing going concern doubts.
NASDAQ
Lexaria Bioscience Corp.'s annual 10-K filing details advancements in its DehydraTECH drug delivery platform, focusing on GLP-1/GIP drugs and hypertension treatments.